Adaptive Biotechnologies spent six years losing money at a scale that would make most companies flinch. Then, on November 4, 2026, CEO Chad Robins called Q3 a “breakthrough quarter” and announced the company’s first GAAP profit. The filed numbers mostly agreed with him. One number, quietly tucked into CFO Kyle Piskel’s remarks, did not.
The heart of it
The math shows a diagnostics business that has genuinely turned a corner: Q3 2026 revenue of $83.9 million beat analyst consensus by roughly 17%, and the company posted its first quarterly profit in its history. The mood, measured by a price-to-sales ratio sitting well above the decade median (our data), says the market is paying nearly twice the historical average for each dollar of sales. The open question is whether the Immune Medicine separation, promised by year-end, delivers the clean story that price implies, or whether it surfaces costs the current multiple hasn’t priced.
The exchange that defined the call
Piskel’s line was precise: the company does not anticipate GAAP net income or positive earnings per share for Q4 2026 or the full year. That is a strange sentence to deliver two minutes after celebrating a profitable quarter. A business that earned a few million dollars in Q3 is guiding, in the same breath, to a full-year loss. The arithmetic is not hard: three quarters of losses followed by one quarter of profit do not sum to annual profit. But the juxtaposition is the story, because Robins had framed Q3 as a turning point, not a one-off.
The filed numbers support Piskel, not the framing. The 10-K for fiscal year 2025 shows a net margin of negative 21.5%, the best in the company’s history but still deeply negative. Our data shows the company has never posted a profitable full fiscal year. One quarter of slim net income, against total operating expenses running at a substantial annual rate, means Q4 would need to be extraordinary to close the gap. Piskel said it won’t be.
What the volume numbers actually show
Strip away the profitability debate and the MRD diagnostics business is doing something real. Nearly 40,000 clonoSEQ tests were delivered in Q3 2026, up 46% from the same quarter a year earlier. To put that in human terms: clonoSEQ detects cancer cells left behind after treatment, at a sensitivity so fine it can find one malignant cell among a million healthy ones. More tests mean more oncologists are ordering it, which means more patients are being monitored with it. That is not a financial abstraction.
The volume growth is also geographically interesting. Community oncology practices, the smaller clinics that treat most cancer patients outside major academic centers, now account for more than a third of total volume, according to the Q3 call. Blood-based testing, which is easier to administer than bone marrow draws, has crossed the majority of total volume. Both shifts point to a test moving from specialist curiosity to routine practice, which is the commercial trajectory that justifies the revenue guidance raise.
The clinical tailwind is real too. In September 2026, the NCCN updated its multiple myeloma guidelines to specifically name clonoSEQ as the preferred assay for MRD assessment. Guidelines like these function as purchasing instructions for hospital systems: when NCCN names a test, procurement committees follow. That update did not appear in the Q3 filing as a revenue line, but it is the kind of structural change that shows up in volume numbers two or three quarters later.
The debt that disappeared
One filed fact from the Q3 10-Q deserves more attention than it received on the call. As of September 30, 2026, Adaptive had fully eliminated a revenue interest liability that stood at $131 million at the end of 2025. A revenue interest liability works like this: a company borrows money and repays it as a percentage of future sales rather than fixed installments. Eliminating it means every dollar of future MRD revenue now stays with the company instead of flowing partly to a creditor. That is structurally significant for margins, even if it doesn’t show up as a headline number.
The cash position as of September 30 gives the company more than a year of operating expenses in reserve at current burn rates, which gives the Immune Medicine separation process real negotiating room. A separation done from a position of cash strength looks different from one done under duress.
The Immune Medicine question management couldn’t fully answer
The strategic review of the Immune Medicine business is the piece of the call where the filed numbers and management’s language diverge most visibly. Robins promised a “path forward” by year-end 2026. The Q3 10-Q describes the review as ongoing and notes that Immune Medicine revenue is expected to decline in the near term, partly because the Genentech collaboration ended in February 2026. The Pfizer target discovery agreement, signed in December 2025 and potentially worth up to $890 million in milestones, is the replacement anchor. But milestone payments are contingent on scientific outcomes that no filing can guarantee.
The honest read is that Immune Medicine is a business in transition being carried by a diagnostics engine. The separation, if it happens cleanly, would let investors price each piece on its own merits. If it stalls or surfaces unexpected liabilities, the current price-to-sales ratio, nearly double the decade median, per our data, leaves little room for disappointment.
Reading the numbers
- $83.9 million Q3 2026 revenue: total sales for the quarter ended September 30, 2026, per the 10-Q filed with the SEC. This beat the Zacks consensus of $71.83 million by about $12 million, per Zacks. A household analogy: if a small business expected to bill $72,000 in a month and actually billed $84,000, the owner would call it a good month, but would not yet call the business profitable for the year.
- 76% gross margin: of every dollar of Q3 revenue, 76 cents remained after the direct cost of running the tests. That is a high-quality margin for a diagnostics company, meaning the business keeps most of what it charges before paying for research, sales, and administration.
- $400.2 million cash: cash and liquid investments on hand as of September 30, 2026, per the Q3 10-Q. With annual operating expenses guided to roughly $350 million, this represents more than a year of runway. A household with $400,000 in savings and $350,000 in annual expenses has breathing room, but not indefinite comfort.
- Price-to-sales of 15.7 vs. decade median of 8.9: the price-to-sales ratio (the market’s total value of the company divided by its annual revenue) is a way to measure what the market pays per dollar of sales. At 15.7, investors are paying nearly $16 for each dollar of annual revenue. The company’s own ten-year median is $8.90. That gap is the mood premium, our data’s term for what the market pays above what the filed history alone would justify.
Sources
- 10-Q for quarter ended September 30, 2026 (SEC EDGAR)
- 10-K for fiscal year ended December 31, 2025 (SEC EDGAR)
- Adaptive Biotechnologies Q3 2026 press release (BioSpace)
- Adaptive raises 2026 MRD guidance (Seeking Alpha)
- Q3 2026 earnings call highlights (GuruFocus)
- NCCN guidelines update, September 2026 (Adaptive IR)
- Q3 key metrics vs. estimates (Zacks)
- Q3 FY26 results summary (ScanX)
